SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is experiencing heightened volatility and aggressive price action as investors grapple with conflicting signals regarding the war in Iran, surging crude oil prices, and President Trumps vague timeline for an exit. The community is sharply divided, with traders debating whether the market's resilience represents a genuine bull trap or a broader, manipulated effort by institutions to provide exit liquidity before a potential holiday-induced selloff.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as the community celebrates the successful Artemis II launch and anticipates the company's pivotal role in lunar infrastructure. Investors are actively discussing a potential short squeeze fueled by high volume and institutional interest, while debating the impact of upcoming NASA contract awards and the broader momentum in the space sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility and heavy trading volume as markets closely track heightened geopolitical tensions in the Middle East and ongoing uncertainty surrounding the Strait of Hormuz. Community sentiment is deeply divided, with many traders actively debating whether the current price action represents a speculative bubble fueled by geopolitical headlines or a structural supply shock that could drive oil significantly higher.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened volatility as investors weigh the company's $14.2B strategic buyback of its Fab 34 stake against broader market instability and geopolitical tensions. While bulls focus on the turnaround potential and long-term capital strength, the community remains deeply divided, with many debating the impact of macroeconomic headwinds and sector-wide sentiment on the stock's immediate direction.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing intense volatility as investors weigh the impact of shifting geopolitical tensions and contradictory messaging from the White House regarding the Iran conflict. Market participants are actively debating whether the recent market resilience signals a robust bottom or if retail traders are being trapped by institutional liquidity as macroeconomic uncertainty persists.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is capturing community attention as investors anticipate a major "Kodak moment" driven by the company's strategic pivot into domestic pharmaceutical API manufacturing and advanced materials. Discussion is currently focused on the potential for upcoming government contracts to strengthen the supply chain, alongside signs of operational growth in its film and print segments.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing extreme volatility as it undergoes S&P 500 index inclusion, driving a surge of forced institutional buying that has captured significant market attention. The community is sharply divided, with bulls pointing to the company's critical role in AI infrastructure and hyperscaler partnerships, while skeptical traders warn of unsustainable valuations and aggressive short-term price swings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high-conviction buying as investors anticipate the upcoming BlueBird 7 launch and broader growth in the space infrastructure sector. Community discussion remains heavily polarized between bulls positioning for a potential squeeze or SpaceX IPO spillover and bears expressing skepticism over execution timelines and macroeconomic volatility.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense speculative activity driven by reports that Amazon is in advanced discussions to acquire the company to bolster its satellite infrastructure and compete with SpaceX's Starlink. The community is actively debating the strategic value of Globalstar's unique satellite spectrum, the complexities of existing partnerships with major tech players, and the potential for a high-stakes bidding war between industry titans.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is currently surging following the announcement of a new volume order for 800G data center transceivers from a major hyperscale client, fueling intense discussion regarding the company's role in AI infrastructure. While the community is actively debating the stock's parabolic trajectory and potential for further momentum, many traders remain hyper-focused on its high volatility and the ongoing influence of institutional positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<ul class="summary-bullets"><li>During the company’s annual meeting in July, shareholders authorized the board to finalize a reverse split within a 1-for-6 to 1-for-20 range.</li><li>The stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 30.</li><li>The company’s net loss for the third quarter widened to $7.5 million from $5.1 million during the year-ago period.</li></ul>Aptevo Therapeutics Inc. (APVO) stock slumped 45% to an all-time low on Friday after the company announced a 1-for-18 reverse stock split, effective after market hours on December 29.The reverse split will consolidate 18 outstanding shares into one, with split-adjusted trading set to begin on the Nasdaq Capital Market on December 30. The move will cut Aptevo’s issued and outstanding shares from about 18 million to roughly a million.Shareholders approved the proposal at the company’s annual meeting on July 24, authorizing the board to finalize a reverse split within a 1-for-6 to 1-for-20 range. The board set the final ratio on December 17.A reverse stock split is aimed at maintaining the stock’s compliance with Nasdaq’s listing requirements by meeting the $1 minimum bid price requirement.<h2 class="st-heading-2">Aptevo’s Q3 Highlights</h2>The company’s net loss for the third quarter (Q3) widened to $7.5 million, or $2.23 per share, from a loss of $5.1 million, or $357.86 per share, in the previous corresponding period.It raised $18.7 million during the quarter and an additional $4.1 million after quarter-end, extending its cash runway into the fourth quarter (Q4) of 2026. Aptevo said the runway would support key clinical milestones next year.Following those results, Aptevo introduced its trispecific antibody, APVO451, designed to counter immune suppression in solid tumors and built on the same binding domain as its lead candidate, Mipletamig, which has demonstrated a favorable safety profile.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APVO">Aptevo Therapeutics</a> trended in the 'bearish' territory at the time of writing.<figure class="image"><img style="aspect-ratio:922/97;" src="https://news.stocktwits-cdn.com/APVO_png_7ab961f5fc.webp" alt="APVO.png" width="922" height="97"><figcaption>APVO's Sentiment Meter and Message Volumes at 10:45 a.m. ET on Dec. 26, 2025 | Source: Stocktwits</figcaption></figure>One user was hopeful of a buyout following the reverse split.<stembedurl>https://stocktwits.com/DonZulu/message/640151182</stembedurl>Another user said that the stock could have an attractive setup on Tuesday next week, with the 1-day moving average convergence divergence (MACD) a key indicator for potential entry.<stembedurl>https://stocktwits.com/GoImugene/message/640157497</stembedurl>Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mag-7-2025-review-on-charts/cLeU7wOREwN">As 2025 Bids Adieu, A Look At How Mag 7 Stocks Are Positioned On Charts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Plug Power said it was impacted by the speed and development of hydrogen economy.

Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval

The move will cut Aptevo’s issued and outstanding shares from about 18 million to roughly a million.

Equity

What's Going On With Aptevo Therapeutics Stock Today?

Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.read more...

Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aptevo Therapeutics (APVO) announced on Tuesday that a 100% remission rate was observed in a cohort of its Phase 1b/2 trial evaluating Mipletamig, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/mipletamig-delivers-100-remission-rate-cohort-3-rainier-trial">study</a> enrolled patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome were observed in the trial or among any frontline patients treated with Mipletamig to date, the company said.The 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy, the company said. It added that 40% of treated patients achieved minimal residual disease (MRD)-negative status, a critical marker of remission.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/APVO">APVO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. Shares of the company traded 8% higher at the time of writing.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_05_PM_png_6c3f4781c1.webp" alt="APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about a potential dip in the share price.<stembedurl>https://stocktwits.com/WEL16/message/628866258</stembedurl>Another highlighted the drop in share price after the initial jump following the news.&nbsp;<stembedurl>https://stocktwits.com/Avior68/message/628866230</stembedurl>The company said that it is actively enrolling patients for the next cohort at the next dose levels and will present current findings at a medical conference in the last quarter.APVO stock is down by 98% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-fda-alleges-novo-nordisk-video-on-weight-loss-drugs-featuring-oprah-winfrey-is-false-or-misleading/chwyFEyRdzF">US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort

The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.

Shares of Aptevo Therapeutics Inc. (APVO) rocketed 41% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-21-million-registered-direct-offering-and">said</a> it is looking to raise about $2.1 million in a registered direct offering and warrants sale.The company said it has entered into definitive securities purchase agreements for the purchase and sale of 1.76 million shares of its common stock in a registered direct offering and warrants to purchase up to 3.5 million shares of common stock in a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant.The warrants will have an exercise price of $1.19 per share and will expire five years from the initial exercise date.The offering is expected to close on or about April 4.The company will use the net proceeds from the offering for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.On Stocktwits, retail investor sentiment about Aptevo jumped from ‘extremely bearish’ to ‘extremely bullish’ territory (97/100), hitting a one-year high. At the same time, message volume touched ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:652/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_11_35_45_AM_png_96a7494386.webp" alt="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK" width="652" height="153"><figcaption>APVO's Sentiment Meter and Message Volume as of 11:35 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the registered direct offering may be a “bailout” to institutions who were short.&nbsp;<stembedurl>https://stocktwits.com/leon_dedrick/message/610264441</stembedurl>Another user, however, expressed optimism about the share price rising to $3.<stembedurl>https://stocktwits.com/Bulltacos/message/610259261</stembedurl><a href="https://stocktwits.com/symbol/APVO">APVO shares</a> have lost over 55% this year and nearly all its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK">Trump’s Liberation Day Impact – Steel Stocks Tumble With Broader Market, UBS Flags Tariffs As 'Incremental Negative' For These Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail  Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in volatile trading.&nbsp;The stock drew significant heavy interest on Stocktwits, reaching the top 15 trending symbols list, where sentiment turned ‘extremely bullish’ amid a sharp rise in message volume.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/APVO_sentiment_and_message_volume_on_Dec_12_f6c2ca53dd.png" alt="APVO sentiment and message volume on Dec 12.png" width="1314" height="320"><figcaption>APVO sentiment and message volume on Dec 12 as of 11:45 am ET | source: Stocktwits</figcaption></figure>The company announced that all patients with acute myeloid leukemia (AML) treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.&nbsp;This includes two patients who experienced complete remission with 100% cancer cell elimination.&nbsp;The trial is exploring mipletamig as frontline therapy in combination with venetoclax and azacitidine, the current standard of care for AML.Retail traders speculated heavily on the stock’s movements, attributing volatility to its small public float of around 500,000 shares.&nbsp;Optimistic users expressed confidence in the company’s long-term potential, with one noting that they had bought 1,000 shares of Aptevo.Aptevo’s oncology pipeline targets aggressive forms of cancer. Other highlights include:• ALG.APV-527: Currently in Phase 1 for 5T4-expressing solid tumors like breast, colon, and non-small cell lung cancers. Preliminary data presented at leading oncology conferences has been positive.• Other preclinical candidates, including APVO711 (immune checkpoint blockade and activator) and APVO603 (dual co-stimulatory solid tumor targeting), are designed for precision cancer treatments.Aptevo stock remains down over 96% year-to-date, reflecting other ongoing challenges. Its current market cap is just over $5 million.Still, retail investors remain cautiously optimistic for now as the company builds on promising clinical data while addressing broader market pressures.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

APVO
Aptevo Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APVO News

APVOAptevo Therapeutics Inc